The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
2017
Complete remission (CR) rates for multiple myeloma (MM) have increased to 60% with current treatment approaches, including high dose melphalan-based autologous stem cell transplant (ASCT) and novel agents, and are associated with improved survival.[1][1]–[3][2] Despite this improvement, highly
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
14
References
15
Citations
NaN
KQI